Recurrent Hepatocellular Carcinoma

Percutaneous Radiofrequency Ablation after Hepatectomy

Dongil Choi, Hyo K. Lim, Min Ju Kim, Sung Hoon Lee, Seung Hoon Kim, Won Jae Lee, Jae Hoon Lim, Jae Won Joh, Yong Il Kim

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

PURPOSE: To evaluate the therapeutic efficacy and safety of percutaneous radiofrequency (RF) ablation for recurrent hepatocellular carcinoma (HCC) in the liver after hepatectomy. MATERIALS AND METHODS: Forty-five patients with 53 recurrent HCC tumors in the liver underwent percutaneous RF ablation with ultrasonographic guidance. All patients had a history of hepatic resection for HCC. The mean diameter of recurrent tumors was 2.1 cm (range, 0.8-4.0 cm). All patients were followed up for at least 10 months after ablation (range, 10-40 months; mean, 23 months). Therapeutic efficacy and complications were evaluated with multiphase helical computed tomography (CT) at regular follow-up visits. Overall and disease-free survival rates were calculated. RESULTS: At follow-up CT after initial RF ablation, 11 (21%) of 53 ablated HCC tumor sites showed residual tumor or local tumor progression. After additional RF ablation, complete ablation of 46 (87%) of 53 tumors was attained. Also at initial follow-up CT, before either additional RF ablation or other treatment was performed, 21 (47%) of 45 patients were found to have 41 new HCC tumors at other liver sites. Of these, nine tumors in eight patients were treatable with a second application of RF ablation. Overall survival rates at 1, 2, and 3 years were 82%, 72%, and 54%, respectively. No deaths or complications requiring further treatment occurred as a result of RF ablation. CONCLUSION: Percutaneous RF ablation is an effective and safe method for treating recurrent HCC in the liver after hepatectomy, with a good overall patient survival rate.

Original languageEnglish
Pages (from-to)135-141
Number of pages7
JournalRadiology
Volume230
Issue number1
DOIs
Publication statusPublished - 2004 Jan 1
Externally publishedYes

Fingerprint

Hepatectomy
Hepatocellular Carcinoma
Neoplasms
Liver
Survival Rate
Tomography
Spiral Computed Tomography
Residual Neoplasm
Therapeutics
Disease-Free Survival
Safety

Keywords

  • Liver neoplasms, therapy
  • Liver, interventional procedures
  • Liver, surgery
  • Radiofrequency (RF) ablation

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Choi, D., Lim, H. K., Kim, M. J., Lee, S. H., Kim, S. H., Lee, W. J., ... Kim, Y. I. (2004). Recurrent Hepatocellular Carcinoma: Percutaneous Radiofrequency Ablation after Hepatectomy. Radiology, 230(1), 135-141. https://doi.org/10.1148/radiol.2301021182

Recurrent Hepatocellular Carcinoma : Percutaneous Radiofrequency Ablation after Hepatectomy. / Choi, Dongil; Lim, Hyo K.; Kim, Min Ju; Lee, Sung Hoon; Kim, Seung Hoon; Lee, Won Jae; Lim, Jae Hoon; Joh, Jae Won; Kim, Yong Il.

In: Radiology, Vol. 230, No. 1, 01.01.2004, p. 135-141.

Research output: Contribution to journalArticle

Choi, D, Lim, HK, Kim, MJ, Lee, SH, Kim, SH, Lee, WJ, Lim, JH, Joh, JW & Kim, YI 2004, 'Recurrent Hepatocellular Carcinoma: Percutaneous Radiofrequency Ablation after Hepatectomy', Radiology, vol. 230, no. 1, pp. 135-141. https://doi.org/10.1148/radiol.2301021182
Choi, Dongil ; Lim, Hyo K. ; Kim, Min Ju ; Lee, Sung Hoon ; Kim, Seung Hoon ; Lee, Won Jae ; Lim, Jae Hoon ; Joh, Jae Won ; Kim, Yong Il. / Recurrent Hepatocellular Carcinoma : Percutaneous Radiofrequency Ablation after Hepatectomy. In: Radiology. 2004 ; Vol. 230, No. 1. pp. 135-141.
@article{27b636d3225e40ef93db56e3f0c76556,
title = "Recurrent Hepatocellular Carcinoma: Percutaneous Radiofrequency Ablation after Hepatectomy",
abstract = "PURPOSE: To evaluate the therapeutic efficacy and safety of percutaneous radiofrequency (RF) ablation for recurrent hepatocellular carcinoma (HCC) in the liver after hepatectomy. MATERIALS AND METHODS: Forty-five patients with 53 recurrent HCC tumors in the liver underwent percutaneous RF ablation with ultrasonographic guidance. All patients had a history of hepatic resection for HCC. The mean diameter of recurrent tumors was 2.1 cm (range, 0.8-4.0 cm). All patients were followed up for at least 10 months after ablation (range, 10-40 months; mean, 23 months). Therapeutic efficacy and complications were evaluated with multiphase helical computed tomography (CT) at regular follow-up visits. Overall and disease-free survival rates were calculated. RESULTS: At follow-up CT after initial RF ablation, 11 (21{\%}) of 53 ablated HCC tumor sites showed residual tumor or local tumor progression. After additional RF ablation, complete ablation of 46 (87{\%}) of 53 tumors was attained. Also at initial follow-up CT, before either additional RF ablation or other treatment was performed, 21 (47{\%}) of 45 patients were found to have 41 new HCC tumors at other liver sites. Of these, nine tumors in eight patients were treatable with a second application of RF ablation. Overall survival rates at 1, 2, and 3 years were 82{\%}, 72{\%}, and 54{\%}, respectively. No deaths or complications requiring further treatment occurred as a result of RF ablation. CONCLUSION: Percutaneous RF ablation is an effective and safe method for treating recurrent HCC in the liver after hepatectomy, with a good overall patient survival rate.",
keywords = "Liver neoplasms, therapy, Liver, interventional procedures, Liver, surgery, Radiofrequency (RF) ablation",
author = "Dongil Choi and Lim, {Hyo K.} and Kim, {Min Ju} and Lee, {Sung Hoon} and Kim, {Seung Hoon} and Lee, {Won Jae} and Lim, {Jae Hoon} and Joh, {Jae Won} and Kim, {Yong Il}",
year = "2004",
month = "1",
day = "1",
doi = "10.1148/radiol.2301021182",
language = "English",
volume = "230",
pages = "135--141",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "1",

}

TY - JOUR

T1 - Recurrent Hepatocellular Carcinoma

T2 - Percutaneous Radiofrequency Ablation after Hepatectomy

AU - Choi, Dongil

AU - Lim, Hyo K.

AU - Kim, Min Ju

AU - Lee, Sung Hoon

AU - Kim, Seung Hoon

AU - Lee, Won Jae

AU - Lim, Jae Hoon

AU - Joh, Jae Won

AU - Kim, Yong Il

PY - 2004/1/1

Y1 - 2004/1/1

N2 - PURPOSE: To evaluate the therapeutic efficacy and safety of percutaneous radiofrequency (RF) ablation for recurrent hepatocellular carcinoma (HCC) in the liver after hepatectomy. MATERIALS AND METHODS: Forty-five patients with 53 recurrent HCC tumors in the liver underwent percutaneous RF ablation with ultrasonographic guidance. All patients had a history of hepatic resection for HCC. The mean diameter of recurrent tumors was 2.1 cm (range, 0.8-4.0 cm). All patients were followed up for at least 10 months after ablation (range, 10-40 months; mean, 23 months). Therapeutic efficacy and complications were evaluated with multiphase helical computed tomography (CT) at regular follow-up visits. Overall and disease-free survival rates were calculated. RESULTS: At follow-up CT after initial RF ablation, 11 (21%) of 53 ablated HCC tumor sites showed residual tumor or local tumor progression. After additional RF ablation, complete ablation of 46 (87%) of 53 tumors was attained. Also at initial follow-up CT, before either additional RF ablation or other treatment was performed, 21 (47%) of 45 patients were found to have 41 new HCC tumors at other liver sites. Of these, nine tumors in eight patients were treatable with a second application of RF ablation. Overall survival rates at 1, 2, and 3 years were 82%, 72%, and 54%, respectively. No deaths or complications requiring further treatment occurred as a result of RF ablation. CONCLUSION: Percutaneous RF ablation is an effective and safe method for treating recurrent HCC in the liver after hepatectomy, with a good overall patient survival rate.

AB - PURPOSE: To evaluate the therapeutic efficacy and safety of percutaneous radiofrequency (RF) ablation for recurrent hepatocellular carcinoma (HCC) in the liver after hepatectomy. MATERIALS AND METHODS: Forty-five patients with 53 recurrent HCC tumors in the liver underwent percutaneous RF ablation with ultrasonographic guidance. All patients had a history of hepatic resection for HCC. The mean diameter of recurrent tumors was 2.1 cm (range, 0.8-4.0 cm). All patients were followed up for at least 10 months after ablation (range, 10-40 months; mean, 23 months). Therapeutic efficacy and complications were evaluated with multiphase helical computed tomography (CT) at regular follow-up visits. Overall and disease-free survival rates were calculated. RESULTS: At follow-up CT after initial RF ablation, 11 (21%) of 53 ablated HCC tumor sites showed residual tumor or local tumor progression. After additional RF ablation, complete ablation of 46 (87%) of 53 tumors was attained. Also at initial follow-up CT, before either additional RF ablation or other treatment was performed, 21 (47%) of 45 patients were found to have 41 new HCC tumors at other liver sites. Of these, nine tumors in eight patients were treatable with a second application of RF ablation. Overall survival rates at 1, 2, and 3 years were 82%, 72%, and 54%, respectively. No deaths or complications requiring further treatment occurred as a result of RF ablation. CONCLUSION: Percutaneous RF ablation is an effective and safe method for treating recurrent HCC in the liver after hepatectomy, with a good overall patient survival rate.

KW - Liver neoplasms, therapy

KW - Liver, interventional procedures

KW - Liver, surgery

KW - Radiofrequency (RF) ablation

UR - http://www.scopus.com/inward/record.url?scp=0346218105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346218105&partnerID=8YFLogxK

U2 - 10.1148/radiol.2301021182

DO - 10.1148/radiol.2301021182

M3 - Article

VL - 230

SP - 135

EP - 141

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 1

ER -